Metabolomic Characteristics of Patients With Non-small Cell Lung Cancer in Plasma, Tissue and Exhaled Breath Condensate

Investigators collected tissue and plasma samples from patients with benign pulmonary nodules and non-small cell lung cancer (NSCLC). Exhaled breath condensate (EBC) samples were obtained from these patients using a breath condenser. Differential metabolites were identified in samples from 22 NSCLC patients and 20 benign controls using ultra-performance liquid chromatography-high resolution mass spectrometry-based untargeted metabolomics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Sex eligibility

All sexes

Study type

Observational

Primary location

People's Hospital of Xinjiang Uygur Autonomous Region

Ürümqi, 830000, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with non-small cell lung cancer or benign pulmonary nodules

Exclusion criteria

Metastatic lung cancer

Treatment and study plan

Primary outcomes

Untargeted metabolomics

Time frame: 2022-2026

Sponsors and collaborators

Lead sponsor

People's Hospital of Xinjiang Uygur Autonomous Region

Other

Registry information

Official study title

Metabolomic Characteristics of Patients With Non-small Cell Lung Cancer in Plasma, Tissue and Exhaled Breath Condensate: A Case-control Study

Important dates

Study start: 2022
Primary completion: 2025
Study completion: 2025
First posted: Apr 15, 2026
Registry last updated: Apr 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed